Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab in Combination With Irinotecan for Malignant Gliomas

NCT00268359 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00268359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab in Combination With Irinotecan for Malignant Gliomas
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
October 31, 2009
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors